The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $17.88 in the prior trading day, Cullinan Therapeutics Inc (NASDAQ: CGEM) closed at $18.06, up 1.01%. In other words, the price has increased by $1.01 from its previous closing price. On the day, 0.7 million shares were traded. CGEM stock price reached its highest trading level at $19.19 during the session, while it also had its lowest trading level at $17.95.
Ratios:
Our goal is to gain a better understanding of CGEM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.07 and its Current Ratio is at 17.07. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 01 ’24 when Savill Corrine sold 40,000 shares for $16.18 per share. The transaction valued at 647,200 led to the insider holds 165,990 shares of the business.
Savill Corrine sold 40,000 shares of CGEM for $563,600 on Jan 29 ’24. The Chief Business Officer now owns 165,990 shares after completing the transaction at $14.09 per share. On Jan 23 ’24, another insider, Savill Corrine, who serves as the Chief Business Officer of the company, sold 21,316 shares for $12.46 each. As a result, the insider received 265,597 and left with 165,990 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGEM now has a Market Capitalization of 777764736 and an Enterprise Value of 314480544.
Stock Price History:
Over the past 52 weeks, CGEM has reached a high of $20.62, while it has fallen to a 52-week low of $7.64. The 50-Day Moving Average of the stock is 4.28%, while the 200-Day Moving Average is calculated to be 51.82%.
Shares Statistics:
The stock has traded on average 487.02K shares per day over the past 3-months and 737550 shares per day over the last 10 days, according to various share statistics. A total of 42.90M shares are outstanding, with a floating share count of 26.36M. Insiders hold about 38.80% of the company’s shares, while institutions hold 56.13% stake in the company. Shares short for CGEM as of 1711584000 were 1436008 with a Short Ratio of 2.95, compared to 1709164800 on 694101. Therefore, it implies a Short% of Shares Outstanding of 1436008 and a Short% of Float of 4.099999700000001.
Earnings Estimates
Cullinan Therapeutics Inc (CGEM) is currently under the scrutiny of Compugen Ltd. analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $25.05, with high estimates of $44.73 and low estimates of $18.06.
